Literature DB >> 16786255

Dietary intervention and oxidative phosphorylation capacity.

Eva Morava1, Richard Rodenburg, Heidi Zweers van Essen, Maaike De Vries, Jan Smeitink.   

Abstract

Secondary deterioration of mitochondrial function has been reported in patients with anorexia and cancer-related malnutrition. Inadequate nutrition, failure to thrive and feeding problems are also common symptoms in children with primary oxidative phosphorylation defects. As a standard intervention protocol we advise an age-appropriate diet and energy intake in our patients diagnosed with a mitochondrial dysfunction. By comparing the results of the first and the second samples from a group of children who underwent repeated muscle biopsies, we observed biochemical improvement in the mitochondrial function in 7 out of 10 patients following dietary advice and intervention. We suggest evaluating the nutritional state by interpretation of the skeletal muscle biochemistry in patients with a suspected oxidative phosphorylation defect. Since an insufficient dietary intake could play a role in secondary mitochondrial dysfunction, nutritional intervention should be performed prior to the biopsy. On the other hand, our data suggest that optimizing the nutritional and energy intake might also improve the utilization of the residual mitochondrial energy-generating capacity in patients with primary oxidative phosphorylation defects.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16786255     DOI: 10.1007/s10545-006-0227-x

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  11 in total

Review 1.  Therapies for mitochondrial diseases and current clinical trials.

Authors:  Ayman W El-Hattab; Ana Maria Zarante; Mohammed Almannai; Fernando Scaglia
Journal:  Mol Genet Metab       Date:  2017-09-18       Impact factor: 4.797

2.  Mitochondrial medicine.

Authors:  Saskia Koene; Jan Smeitink
Journal:  J Inherit Metab Dis       Date:  2011-04       Impact factor: 4.982

Review 3.  Advances in drug therapy for mitochondrial diseases.

Authors:  Lufei Zhang; Zhaoyong Zhang; Aisha Khan; Hui Zheng; Chao Yuan; Haishan Jiang
Journal:  Ann Transl Med       Date:  2020-01

Review 4.  Recent topics: the diagnosis, molecular genesis, and treatment of mitochondrial diseases.

Authors:  Kei Murayama; Masaru Shimura; Zhimei Liu; Yasushi Okazaki; Akira Ohtake
Journal:  J Hum Genet       Date:  2018-11-21       Impact factor: 3.172

5.  A modern approach to the treatment of mitochondrial disease.

Authors:  Sumit Parikh; Russell Saneto; Marni J Falk; Irina Anselm; Bruce H Cohen; Richard Haas; The Mitochondrial Medicine Society
Journal:  Curr Treat Options Neurol       Date:  2009-11       Impact factor: 3.598

Review 6.  Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis.

Authors:  D A Rossignol; R E Frye
Journal:  Mol Psychiatry       Date:  2011-01-25       Impact factor: 15.992

Review 7.  Mitochondrial disorders: challenges in diagnosis & treatment.

Authors:  Nahid Akhtar Khan; Periyasamy Govindaraj; Angamuthu Kannan Meena; Kumarasamy Thangaraj
Journal:  Indian J Med Res       Date:  2015-01       Impact factor: 2.375

8.  Feeding difficulties, a key feature of the Drosophila NDUFS4 mitochondrial disease model.

Authors:  Sarah Foriel; Julien Beyrath; Ilse Eidhof; Richard J Rodenburg; Annette Schenck; Jan A M Smeitink
Journal:  Dis Model Mech       Date:  2018-03-27       Impact factor: 5.758

Review 9.  Biomarkers in autism.

Authors:  Andre A S Goldani; Susan R Downs; Felicia Widjaja; Brittany Lawton; Robert L Hendren
Journal:  Front Psychiatry       Date:  2014-08-12       Impact factor: 4.157

10.  Variants in NGLY1 lead to intellectual disability, myoclonus epilepsy, sensorimotor axonal polyneuropathy and mitochondrial dysfunction.

Authors:  Daan M Panneman; Saskia B Wortmann; Charlotte A Haaxma; Peter M van Hasselt; Nicole I Wolf; Yvonne Hendriks; Benno Küsters; Sjenet van Emst-de Vries; Els van de Westerlo; Werner J H Koopman; Liesbeth Wintjes; Frans van den Brandt; Maaike de Vries; Dirk J Lefeber; Jan A M Smeitink; Richard J Rodenburg
Journal:  Clin Genet       Date:  2020-01-30       Impact factor: 4.438

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.